Recent Updates
Recently added Catalysts
ERAS Positive Sentiment Score: 75/100

Anticipated key milestones - Updated

Wednesday, February 8, 2023 1 min read
Key Takeaway: The article outlines the anticipated key milestones for ERAS in their clinical trial programs, notably mentioning the timelines for various trials in 2023 and 2024. The SEACRAFT and HERKULES programs aim to explore treatments for different types of solid tumors and melanoma. Notable trials include ERAS-007 and ERAS-601, which are set to provide preliminary data on the safety and effectiveness of novel combination therapies. The focus on CNS-penetrant therapies indicates a targeted approach to challenging cancers such as glioblastoma multifome.

Market Sentiment Analysis

POSITIVE FACTORS

  • Multiple key milestones anticipated in 2023 and 2024.
  • Focus on innovative treatments for various solid tumors.
  • Positive developments in Phase 1b and Phase 3 trials.
  • Inclusion of CNS-penetrant therapies for challenging cancers.

Full Press Release Details

Program Trial Name 2023 2024 Mechanism Indication SEACRAFT-1 H2 2023 Q2 2024 - Q4 2024 3 Ph 1b FPD Ph 1b combo data RAS Q61X Solid Tumors Naporafenib Pan-RAF inhibitor SEACRAFT-2 H1 2024 3 Ph 3 pivotal FPD NRASm Melanoma HERKULES-1 H1 2024 4
Ph 1b combo data Advanced Solid Tumors ERAS-007 and/or ERAS-601 HERKULES-2 H1 2023 1 Ph 1b combo data Lung Cancers (MAPKlamp ) ERK1/2 inhibitor and/or HERKULES-3 H1 2023 H2 2023 - H1 2024 SHP2 inhibitor BRAFm CRC and Ph 1b combo data Ph 1b
combo data in BRAFm CRC RASm GI Cancers FLAGSHP-1 H1 2024 H1 2023 ERAS-601 2 Triple WT CRC and Ph 1b dose escalation Ph 1b combo data in SHP2 inhibitor (incl. MTD) data HPV-neg HNSCC HPV-neg HNSCC ERAS-801 THUNDERBBOLT-1 H2 2023 CNS-penetrant Ph 1
data in rGBM Glioblastoma Multiforme EGFR inhibitor ERAS-3490 AURORAS-1 2024 CNS-penetrant Ph 1 data KRAS G12Cm NSCLC KRAS G12C inhibitor 1 ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor) together comprise our first innovative
MAPKlamp 2 Triple wildtype CRC is KRASwt, NRASwt, and BRAFwt 3 FPD = first patient dose 4 Data to include preliminary combination safety and pharmacokinetics to support combination dose expansion

Frequently Asked Questions

What is the SEACRAFT-1 trial focused on?

SEACRAFT-1 targets RAS Q61X solid tumors with combination data.

When does the HERKULES-2 trial begin?

The HERKULES-2 trial is set to start in H1 2024.

What type of inhibitor is ERAS-007?

ERAS-007 is an oral ERK1/2 inhibitor.

What cancers are targeted by the THUNDERBBOLT-1 trial?

THUNDERBBOLT-1 focuses on Glioblastoma Multiforme.

What does FPD stand for in the trials?

FPD stands for first patient dose.

Tags: ERAS Viatris Investor Conferences Healthcare clinical trials solid tumors melanoma KRAS
Last updated: Feb 8, 2023